PenicillinX

Development preview. Not validated. Not for clinical decision making.

No cross-reactivity Cross-reactivity Discrepancy No data Same drug R1-driven R2-exclusive Both

Please select an antibiotic.

PenicillinX

This is a development preview for PenicillinX (Penicillin Cross reactivity). It demonstrates similar molecular substructures across beta-lactam antibiotics.

Use case

Where a patient has a history of hypersensitivity to more than one beta-lactam, there is an opportunity to examine shared molecular structures to determine the causative substructure. This can aid specialist clinicians in selecting beta-lactams less likely to result in hypersensitivity for potential challenge.

Warning

PenicillinX is still under development. The results presented are not validated and must not be used to assist in any kind of clinical decision making.

Provided free under the terms of the AGPL v3.0 licence. By using this software you agree to the terms of the licence and agree to not use any results output by this program to any extent in any clinical decision making.

Decline

About

PenicillinX predicts which beta-lactam antibiotics are likely to cross-react by measuring the chemical similarity of their side chains.

Why side chains

Every drug here shares the same beta-lactam core, so the core cannot explain why a patient reacts to one drug and tolerates another. Hypersensitivity is instead largely driven by the side chains hanging off that core: the R1 group, and for cephalosporins the R2 group. Each molecule is drawn with its beta-lactam ring shaded blue so you can see the shared anatomy, and matched side chain atoms circled in red (R1) or blue (R2).

Does this use AI?

No. This uses established, deterministic chemoinformatic algorithms that analyse and compare the chemical and topographical properties of the target molecular pairs according to pre-determined criteria and similarity thresholds. The advantage of this method is transparency and reproducibility as compared to a machine learning model.

Using the site

Compare answers "my patient reacted to these drugs, what do they share?". Pick up to three antibiotics and see them drawn side by side, with the prediction for every pair underneath.

Matrix shows all 51 antibiotics against each other at once. Cell colour based on Hutten et al. (2025); a black dot is this model's prediction, a blue dot is a prediction based on R2.

Matrix cell colours. (Hutten et al. 2025)
No cross-reactivity
Cross-reactivity
Discrepancy between source studies
No data
Same drug
Model prediction dots
R1-driven
R2-exclusive - R1 similarity fell below threshold
R1 and R2 both flagged independently

The R2-exclusive case is the novel finding of the accompanying work: pairs that look unrelated by their R1 groups, but share an R2 group closely enough to matter.

The ensemble

The model incorporates seven different chemoinformatics algorithms testing molecular similarity. A pair is predicted to cross-react if any of them flag positive. Four compare whole-molecule fingerprints and return a single similarity score; three identify the specific atoms responsible and can therefore drive the highlighting. Where only fingerprint methods are positive, the implicated side chain is shaded as a whole instead, since no individual atoms are identified.

Limitations

Results must not inform clinical decision making to any extent.

Source : AGPL v3.0

Original matrix derived from:Hutten, E.M., Bulatović Ćalasan, M., Trubiano, J.A., Pleijhuis, R.G.-J. and Terreehorst, I. (2025), Discrepancies in Beta-Lactam Antibiotics Cross-Reactivity: Implications for Clinical Practice. Allergy, 80: 3108-3114.